Last Updated: November 8, 2026

Acerus Company Profile

« Back to Dashboard


What is the competitive landscape for ACERUS

ACERUS has two approved drugs.

There are five US patents protecting ACERUS drugs.

Summary for Acerus
US Patents:5
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Acerus

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No 11,419,914 ⤷  Start Trial ⤷  Start Trial
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX Yes Yes 11,090,312 ⤷  Start Trial ⤷  Start Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No 9,539,302 ⤷  Start Trial Y ⤷  Start Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No 12,090,190 ⤷  Start Trial Y ⤷  Start Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No 12,090,190 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Acerus

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 8,877,230 ⤷  Start Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 7,799,761 ⤷  Start Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 7,579,321 ⤷  Start Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 7,579,321 ⤷  Start Trial
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 8,574,622 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Acerus Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2712622 201740002 Slovenia ⤷  Start Trial PRODUCT NAME: DESMOPRESSINE OR ITS ACETATE SALT; NATIONAL AUTHORISATION NUMBER: H/16/02212/001-008; DATE OF NATIONAL AUTHORISATION: 20160818; AUTHORITY FOR NATIONAL AUTHORISATION: SI; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE497271,BE497280; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20160504; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE
3225249 300983 Netherlands ⤷  Start Trial PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
3225249 2019C/520 Belgium ⤷  Start Trial PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622 LUC00015 Luxembourg ⤷  Start Trial PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
2712622 C02712622/01 Switzerland ⤷  Start Trial PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.